CAS: 877877-35-5; N-[4-(2-Tert-Butylphenylsulfonyl)Phenyl]-2,3,4-Trihydroxy-5-(2-Isopropylbenzyl)Benzamide

该化合物是一个复杂的有机化合物,其特点是多功能结构,具有复杂的有机化合物,其特点是:磺酰胺组因其在各种生物活动中的作用而闻名,以及多种羟基组,其潜在溶解性和再活性有作用;散装三丁基和异丙基组的存在表明,该化合物可能表现出严重的阻塞性,影响其与生物目标的互动;该化合物的芳香环提供了稳定性,并可能促进欧元的堆叠相互作用,这对于药物设计和分子识别十分重要;此外,氢氧基组可以参与氢联结,增强其作为药用磷的潜力.

结构式图片

物理性质

MSDS等安全信息

上下游产品

N-[(2-Tert-Butyl-Benzenesulfonyl)-Phenyl]-2,3,4-Trimethoxyl-5-(2-Isopropyl-Benzyl)-Benzamide 913961-14-5

合成工艺路线路线简述

  • 913961-16-7 = 877877-35-5
    反应条件:1.1 Reagents: Butyllithium Solvents: Tetrahydrofuran; -78 °C1.2 -1.3 Reagents: Thionyl Chloride Catalysts: Dimethylformamide Solvents: Benzene; 70 °C2.1 Reagents: Triethylamine Solvents: Dichloromethane; Rt3.1 Reagents: Boron Tribromide Solvents: Dichloromethane; Rt
    标题:Structure-Based Design Of Potent Small-Molecule Inhibitors Of Anti-Apoptotic Bcl-2 Proteins
    作者:Wang,Guoping; Et Al
    参考文献:Journal Of Medicinal Chemistry 日期:2006 卷标:49(21) 页码:6139-6142]

    19728-41-7 = 877877-35-5
    反应条件:1.1 Reagents: Potassium Carbonate Solvents: Dimethylformamide; 100 °C2.1 Reagents: M-Chloroperbenzoic Acid Solvents: Dichloromethane; 0 °C -> Rt2.2 Reagents: Hydrogen Catalysts: Palladium Solvents: Ethyl Acetate3.1 Reagents: Triethylamine Solvents: Dichloromethane; Rt4.1 Reagents: Boron Tribromide Solvents: Dichloromethane; Rt
    标题:Structure-Based Design Of Potent Small-Molecule Inhibitors Of Anti-Apoptotic Bcl-2 Proteins
    作者:Wang,Guoping; Et Al
    参考文献:Journal Of Medicinal Chemistry 日期:2006 卷标:49(21) 页码:6139-6142]

    913961-15-6 = 877877-35-5
    反应条件:1.1 Reagents: Hydrogen Catalysts: Palladium Solvents: Ethyl Acetate1.2 Reagents: Bromine Solvents: Chloroform; -60 °C2.1 Reagents: Butyllithium Solvents: Tetrahydrofuran; -78 °C2.2 -2.3 Reagents: Thionyl Chloride Catalysts: Dimethylformamide Solvents: Benzene; 70 °C3.1 Reagents: Triethylamine Solvents: Dichloromethane; Rt4.1 Reagents: Boron Tribromide Solvents: Dichloromethane; Rt
    标题:Structure-Based Design Of Potent Small-Molecule Inhibitors Of Anti-Apoptotic Bcl-2 Proteins
    作者:Wang,Guoping; Et Al
    参考文献:Journal Of Medicinal Chemistry 日期:2006 卷标:49(21) 页码:6139-6142]

    913961-14-5 = 877877-35-5
    反应条件:1.1 Reagents: Boron Tribromide Solvents: Dichloromethane; Rt
    标题:Structure-Based Design Of Potent Small-Molecule Inhibitors Of Anti-Apoptotic Bcl-2 Proteins
    作者:Wang,Guoping; Et Al
    参考文献:Journal Of Medicinal Chemistry 日期:2006 卷标:49(21) 页码:6139-6142]

    913961-19-0 + 913961-17-8 = 877877-35-5
    反应条件:1.1 Reagents: Triethylamine Solvents: Dichloromethane; Rt2.1 Reagents: Boron Tribromide Solvents: Dichloromethane; Rt
    标题:Structure-Based Design Of Potent Small-Molecule Inhibitors Of Anti-Apoptotic Bcl-2 Proteins
    作者:Wang,Guoping; Et Al
    参考文献:Journal Of Medicinal Chemistry 日期:2006 卷标:49(21) 页码:6139-6142]

    913961-18-9 = 877877-35-5
    反应条件:1.1 Reagents: M-Chloroperbenzoic Acid Solvents: Dichloromethane; 0 °C -> Rt1.2 Reagents: Hydrogen Catalysts: Palladium Solvents: Ethyl Acetate2.1 Reagents: Triethylamine Solvents: Dichloromethane; Rt3.1 Reagents: Boron Tribromide Solvents: Dichloromethane; Rt
    标题:Structure-Based Design Of Potent Small-Molecule Inhibitors Of Anti-Apoptotic Bcl-2 Proteins
    作者:Wang,Guoping; Et Al
    参考文献:Journal Of Medicinal Chemistry 日期:2006 卷标:49(21) 页码:6139-6142]

    7073-94-1 + 2103-57-3 = 877877-35-5
    反应条件:1.1 Reagents: Butyllithium Solvents: Tetrahydrofuran; -78 °C1.2 -2.1 Reagents: Hydrogen Catalysts: Palladium Solvents: Ethyl Acetate2.2 Reagents: Bromine Solvents: Chloroform; -60 °C3.1 Reagents: Butyllithium Solvents: Tetrahydrofuran; -78 °C3.2 -3.3 Reagents: Thionyl Chloride Catalysts: Dimethylformamide Solvents: Benzene; 70 °C4.1 Reagents: Triethylamine Solvents: Dichloromethane; Rt5.1 Reagents: Boron Tribromide Solvents: Dichloromethane; Rt
    标题:Structure-Based Design Of Potent Small-Molecule Inhibitors Of Anti-Apoptotic Bcl-2 Proteins
    作者:Wang,Guoping; Et Al
    参考文献:Journal Of Medicinal Chemistry 日期:2006 卷标:49(21) 页码:6139-6142
📜2,3,4-三甲氧基苯甲醛置于palladium On Activated Charcoal 正丁基锂,氯化亚砜,氢气,溴,三溴化硼,三乙胺,N,N-二甲基甲酰胺体系中,用 四氢呋喃,二氯甲烷,氯仿,乙酸乙酯,苯 作为反应溶剂,化学反应 0.5H,反应生成 N-[4-(2-叔丁基苯磺酰基)苯基]-2,3,4-三羟基-5-(2-异丙基苄基)苯甲酰胺
参考文献:Structure-Based Design Of Potent Small-Molecule Inhibitors Of Anti-Apoptotic Bcl-2 Proteins
标题:Structure-Based Design Of Potent Small-Molecule Inhibitors Of Anti-Apoptotic Bcl-2 Proteins
摘要:A Structure-Based Approach Was Employed To Design A New Class Of Small-Molecule Inhibitors Of Bcl-2. The Most Potent Compound 5 (Tw-37) Binds To Bcl-2 With A K-I Value Of 290 Nm And Also To Bclxl And Mcl-1 With High Affinities. Compound 5 Potently Inhibits Cell Growth In Pc-3 Prostate Cancer Cells With An Ic50 Value Of 200 Nm And Effectively Induces Apoptosis In A Dose-Dependent Manner.
DOI:10.1021/jm060460O

海关参考信息

专利信息


专利号:US-2025289827-A1
优先权日:2022-12-02
标 题:Morphic forms of a mutant braf degrader and methods of manufacture thereof
发明人：YU ROBERT T; HE MINSHENG; SCHNADERBECK MATTHEW J; KREGER BRIDGET; POLLOCK ROY MACFARLANE; JIANG SIYI; LI MEIQI; CHEN BOLU; LU JIANNAN
权利人:C4 THERAPEUTICS INC
摘要:Advantageous isolated morphic forms of (3R)-3-[6-[2-cyano-3-[[ethyl(methyl)sulfamoyl]amino]-6-fluorophenoxy]-4-oxoquinazolin-3-yl]-8-[2-[1-[3-(2,4-dioxo-1,3-diazinan-1-yl)-5-fluoro-1-methylindazol-6-yl]-4-hydroxypiperidin-4-yl]acetyl]-1-oxa-8-azaspiro[4.5]decane (Compound 1), which is a mutant BRAF degrader, and methods to prepare Compound 1 morphic forms for therapeutic applications are provided in the invention. The invention also provides improved methods for the synthesis of Compound 1, new pharmaceutical compositions comprising Compound 1, and new uses of Compound 1.

专利号:US-11285169-B2
优先权日:2013-03-13
标题 :Methods for modulating chemotherapeutic cytotoxicity
发明人：ROBERTS DAVID D; SOTO PANTOJA DAVID R
权利人:US HEALTH
摘要:Methods of reducing cytotoxicity of a chemotherapeutic agent to non-cancer cells by administering to a subject with cancer an effective amount of an agent that inhibits CD47 signaling and a DNA damaging agent, such as an anthracycline, topoisomerase inhibitor, or nucleotide synthesis inhibitor, are provided. Example disclosed methods reduce cardiotoxicity. In one example, the methods include administering to a subject with cancer an effective amount of a CD47 antisense morpholino oligonucleotide and an anthracycline such as doxorubicin. Methods of increasing cytotoxicity of a chemotherapeutic agent in cancer cells by administering to a subject with a tumor an effective amount of an agent that inhibits CD47 signaling and a DNA damaging agent such as an anthracycline, topoisomerase inhibitor, or nucleotide synthesis inhibitor, are also provided. In some embodiments, the inhibitor of CD47 signaling is administered to the subject before, during, or after the administration of the DNA damaging agent.

其他信息查阅

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

实用工具

⚠️全国化工行业净网倡议书
📋制造商识别码
📖 海关编码查询
📝MSDS生成器

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

主要参考文献


1: Guo C, Jiang X, Zhang Y, Bao G. Comprehensive analysis of tumor immune- related gene signature for predicting prognosis, immunotherapy, and drug sensitivity in bladder urothelial carcinoma. Transl Cancer Res. 2024 Dec 31;13(12):6732-6752. doi: 10.21037/tcr-24-1053. Epub 2024 Dec 24.
2: Zhang X, Li J, Li X, Chen Z, Ren D, Zhang S. Adsorption properties and mechanisms of Cd by co-pyrolysis composite material derived from peanut biochar and tailing waste. Environ Geochem Health. 2025 Jan 3;47(2):37. doi: 10.1007/s10653-024-02352-1. 115(5):110673. doi: 10.1016/j.ygeno.2023.110673. Epub 2023 Jun 27.
233:109542. doi: 10.1016/j.exer.2023.109542. Epub 2023 Jun 17.

合成参考文献


参考文献:10.1124/mol.119.115964
摘要:Lee TD, Lee OW, Brimacombe KR, Chen L, Guha R, Lusvarghi S, Tebase BG, Klumpp-Thomas C, Robey RW, Ambudkar SV, Shen M, Gottesman MM, Hall MD. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Molecular Pharmacology. 2019 Nov;96(5):629–40. doi: 10.1124/mol.119.115964.
📝 需求与反馈
尽可能描述清楚需求与问题信息
×

通知